GHB Facts
Depressant;
Description
GHB (gamma-hydroxybutyric acid) — G, liquid G, liquid ecstasy — is a CNS depressant of the hydroxy acid class. GHB suppresses brain activity through GABA-B activation, producing the sedation, relaxation, and euphoria characteristic of depressants.
Subjective effects include euphoria, disinhibition, muscle relaxation, anxiolysis, and amnesia. The experience resembles compressed alcohol intoxication — a warm, sociable loosening that tips quickly into heavy sedation as the dose rises.
GHB produces rapid physical dependence, and only a roughly five-fold span in blood concentration separates euphoria from lethal respiratory depression.[1] Small dose increases cause disproportionately large jumps in blood levels because the body's processing capacity saturates;[2] no antidote exists,[3] and withdrawal progresses faster and more dangerously than with alcohol or benzodiazepines.[4][5]
Dose and durationby route · individual sensitivity varies
Starts in 5 – 30 minLasts 1.5 – 2.5 hoursAfter-effects 2 – 4 hours
Body and dependence
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Physical dependence
- High
- Psychological dependence
- Moderate
- Withdrawal
- Severe · fatal · medical supervision
- Compulsive redosing
- High
Tolerance
- Builds
- Rapid
- Fully resets after
- 10.5 days
- Carries over to
- baclofen;
phenibut; GBL; 1,4-butanediol
Effectslikely at a common dose
- Perception
- Sleep-transition hallucinations;
Vestibular distortion; +9 possible, including Spatial disorientation, Visual acuity suppression, Double vision - Body
- Bodily heaviness;
Body high; Dizziness; Motor control impairment; Muscle relaxation; Physical fatigue; Respiratory depression; Sedation; Tactile euphoria; +17 possible, including Nausea, Vomiting, Nystagmus (eye wobbles) - Thinking
- Cognitive impairment;
Compulsive redosing urge; Decision impairment; Focus suppression; Information processing suppression; Memory suppression; +17 possible, including Analysis suppression, Confusion, Delusions of sobriety - Feeling
- Anxiety suppression;
Euphoria; +8 possible, including Anxiety, Dysphoria, Emotional lability - Self
- Disinhibition;
Sociability enhancement; Social connection; +9 possible, including Communication suppression, Craving, Depersonalization - Time
- none likely · 3 possible, including Temporal disorientation
- Awareness
- none likely · 1 possible
Who shouldn't take it
Combinations64 recorded
Seek help immediately if
- Extreme drowsiness — can't stay awake or be roused
- Confusion, slurred speech, severe loss of coordination
- Slow, shallow, or irregular breathing
- Unconsciousness / unresponsive; limp, floppy body
- Blue lips or fingertips
- Vomiting while sedated (choking / aspiration risk)
- Cold, clammy skin; weak pulse
What to do
- Try to wake them — shout, firm sternal rub
- If unresponsive or breathing is impaired, call emergency services
- Place them in the recovery position — critical, they can choke on vomit
- Monitor breathing continuously; be ready to give rescue breaths / CPR
- Never leave them alone to "sleep it off"
- Do not give other drugs, stimulants, or more depressants
Most depressant overdoses resolve with airway protection, breathing support, and monitoring. The danger is respiratory depression and choking on vomit — sharply worse when combined with opioids or alcohol. GHB/GBL overdoses often involve sudden deep unconsciousness and may self-resolve, but airway protection is essential.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^Busardò FP, Jones AW (2015) GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome — Current Neuropharmacology doi:10.2174/1570159x13666141210215423
- [2]^Palatini P, Tedeschi L, Frison G, et al. (1993) Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers — European Journal of Clinical Pharmacology PMID:8299669
- [3]^Felmlee MA, Morse BL, Morris ME (2021) γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology — The AAPS Journal doi:10.1208/s12248-020-00543-z
- [4]^Moitroux A, Kestens C (2023) Withdrawal syndrome following chronic use of gamma-hydroxybutyric acid (GHB) — Revue medicale de Liege PMID:37560960
- [5]^Wood AML, Schellekens AFA, Dijkstra BAG, Wolf CJH, Beurmanjer H (2025) Development of the Gamma-Hydroxybutyrate Withdrawal Symptom Questionnaire — European Addiction Research doi:10.1159/000545700